Its significance in oncogenesis is highlighted by the plethora of inhibitors (dual PI3K–mTOR, PI3K, Akt and mTOR inhibitors) that are in clinical use or late-stage development for cancer treatment, with promising results in hematologic malignancies [17,18]. This evidence concerns the gene AKT1 and hematologic disorder.